Sugimoto, N.; Noura, S.; Kato, T.; Yoshioka, S.; Hata, T.; Naito, A.; Tei, M.; Tamagawa, H.; Komori, T.; Ide, Y.;
et al. The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine—Including Biomarker Analyses. Cancers 2025, 17, 91.
https://doi.org/10.3390/cancers17010091
AMA Style
Sugimoto N, Noura S, Kato T, Yoshioka S, Hata T, Naito A, Tei M, Tamagawa H, Komori T, Ide Y,
et al. The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine—Including Biomarker Analyses. Cancers. 2025; 17(1):91.
https://doi.org/10.3390/cancers17010091
Chicago/Turabian Style
Sugimoto, Naotoshi, Shingo Noura, Takeshi Kato, Shinichi Yoshioka, Taishi Hata, Atsushi Naito, Mitsuyoshi Tei, Hiroshi Tamagawa, Takamichi Komori, Yoshihito Ide,
and et al. 2025. "The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine—Including Biomarker Analyses" Cancers 17, no. 1: 91.
https://doi.org/10.3390/cancers17010091
APA Style
Sugimoto, N., Noura, S., Kato, T., Yoshioka, S., Hata, T., Naito, A., Tei, M., Tamagawa, H., Komori, T., Ide, Y., Fukuzaki, T., Danno, K., Sawada, G., Kagawa, Y., Shimokawa, T., Miyoshi, N., Ogino, T., Uemura, M., Yamamoto, H.,
... Eguchi, H.
(2025). The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine—Including Biomarker Analyses. Cancers, 17(1), 91.
https://doi.org/10.3390/cancers17010091
